Issue navigation
Volume 7, Issue 1, January 2021
Editorial
Atrial fibrillation in registries
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 1–2, https://doi.org/10.1093/ehjcvp/pvaa142
Original Articles
Atrial Fibrillation
Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 3–10, https://doi.org/10.1093/ehjcvp/pvz063
Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 11–19, https://doi.org/10.1093/ehjcvp/pvz064
Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 20–30, https://doi.org/10.1093/ehjcvp/pvz066
Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 31–39, https://doi.org/10.1093/ehjcvp/pvz070
An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS)
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 40–49, https://doi.org/10.1093/ehjcvp/pvz071
Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 50–58, https://doi.org/10.1093/ehjcvp/pvz072
Reviews
Obesity and atrial fibrillation: making inroads through fat
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 59–67, https://doi.org/10.1093/ehjcvp/pvaa013
Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 68–73, https://doi.org/10.1093/ehjcvp/pvaa047
Correspondence
Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Page 74, https://doi.org/10.1093/ehjcvp/pvaa022
Comment on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Page 75, https://doi.org/10.1093/ehjcvp/pvaa023
Inhibitors of the renin–angiotensin–aldosterone system and COVID-19 in critically ill elderly patients
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 76–77, https://doi.org/10.1093/ehjcvp/pvaa083
Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 1, January 2021, Pages 78–80, https://doi.org/10.1093/ehjcvp/pvaa087
